Table 3.
Comparison of the two groups of patients in terms of intraoperative, postoperative and histopathological results
| Bilirubin ≤75 μmol/L (n = 82) |
Bilirubin > 75 μmol/L (n = 8) |
P value | |
|---|---|---|---|
| Blood loss (L) | 1.4 (0.3–20) | 3.12 (1.4–6.0) | 0.008a |
| Blood replacement (L) | 0.0 (0.0–13.8) | 2.45 (0.6–4.3) | < 0.001a |
| Blood transfusion | 34 (42.0%) | 8 (100%) | 0.011a |
| Operation time (min) | 674.0 (222–1290) | 797.0 (514–960) | 0.156 |
| Type of resection | 0.558 | ||
| Right hepatectomy | 5 (6.1%) | 1 (12.5%) | |
| Right extended hepatectomy | 3 (3.7%) | 0 (0%) | |
| Left hepatectomy | 2 (2.4%) | 1 (12.5%) | |
| Left extended hepatectomy | 2 (2.4%) | 0 (0%) | |
| Right trisectionectomy | 2 (2.4%) | 0 (0%) | |
| Left trisectionectomy | 1 (1.2%) | 0 (0%) | |
| Right hepatectomy + caudate | 26 (31.7%) | 1 (12.5%) | |
| Right extended hepatectomy + caudate | 7 (8.5%) | 0 (0%) | |
| Left hepatectomy + caudate | 12 (14.6%) | 3 (37.5%) | |
| Left extended hepatectomy + caudate | 5 (6.1%) | 0 (0%) | |
| Right trisectionectomy + caudate | 17 (20.7%) | 2 (25%) | |
| Blood vessel reconstruction | 22 (26.8%) | 0 (0%) | 0.210 |
| Portal vein reconstruction | 17 (20.7%) | 0 (0%) | 0.339 |
| Hepatic artery reconstruction | 5 (6.1%) | 0 (0%) | 1.000 |
| Patients with postoperative complications | 46 (56.1%) | 6 (75%) | 0.510 |
| Renal complications | 6 (7.3%) | 3 (37.5%) | 0.036a |
| Urinary tract infection | 1 (1.2%) | 1 (12.5%) | 0.418 |
| Renal failure | 5 (6.1%) | 2 (25%) | 0.225 |
| Patients with complications of grade IIIA or above | 28 (34.1%) | 4 (50%) | 0.612 |
| Grade IIIA | 24 (29.3%) | 3 (37.5%) | 0.936 |
| Grade IIIB | 14 (17.1%) | 1 (12.5%) | 1.000 |
| Grade IVA | 6 (7.3%) | 1 (12.5%) | 1.000 |
| Grade IVB | 0 (0%) | 0 (0%) | /// |
| Grade V | 7 (8.5%) | 4 (50%) | 0.004a |
| In-hospital mortality | 7 (8.5%) | 4 (50%) | 0.004a |
| 30-day mortality | 5 (6.1%) | 2 (25%) | 0.225 |
| 90-day mortality | 8 (9.8%) | 4 (50%) | 0.008a |
| Hospital stay (days) | 20.0 (6–93) | 27.5 (10–214) | 0.228 |
| Pattern of recurrence | 0.394 | ||
| No recurrence | 31 (37.8%) | 5 (62.5%) | |
| Intrahepatic recurrence | 7 (8.5%) | 0 (0%) | |
| Extrahepatic recurrence | 22 (26.8%) | 2 (25%) | |
| Intrahepatic and extrahepatic recurrence | 22 (26.8%) | 1 (12.5%) | |
| Time to recurrence (months) | 16.7 (1.2–218.3) | 11.6 (1.1–24.4) | 0.311 |
| Follow-up duration (months) | 21.6 (0.4–218.3) | 4.1 (0.3–26.6) | 0.008a |
| Resection margin | 1.000 | ||
| Not involved | 44 (53.7%) | 4 (50%) | |
| Involved | 38 (46.3%) | 4 (50%) | |
| Invasion of major branch of portal or hepatic vein | 1.000 | ||
| No | 70 (85.4%) | 7 (87.5%) | |
| Yes | 12 (14.6%) | 1 (12.5%) | |
| Microvascular invasion | 0.429 | ||
| Absent | 55 (67.1%) | 7 (87.5%) | |
| Present | 27 (32.9%) | 1 (12.5%) | |
| Number of lymph node metastasis | 0.0 (0–25) | 0.0 (0–3) | 0.891 |
| Klatskin staging | 0.208 | ||
| I | 12 (15.0%) | 0 (0%) | |
| II | 25 (31.3%) | 3 (37.5%) | |
| IIIA | 2 (2.5%) | 1 (12.5%) | |
| IIIB | 26 (32.5%) | 4 (50%) | |
| IVA | 12 (15.0%) | 0 (0%) | |
| IVB | 3 (3.8%) | 0 (0%) |
Data are shown as number of patient (percent) or median (range)
astatistically significant